Image

Global Immune Repertoire Sequencing Market – Industry Trends and Forecast to 2029

  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Healthcare
  • Upcoming Report
  • Aug 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Immune Repertoire Sequencing Market, By Product Type (Assay Kits and Instruments), Application (Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases and Other), End-User (Diagnostics Labs, Biotechnology and Pharmaceuticals Companies, Academic and Research Institutes and Others) – Industry Trends and Forecast to 2029.

Immune Repertoire Sequencing Market

Global Immune Repertoire Sequencing Market Analysis and Size

Immune repertoire sequencing is widely used in biomarker discovery to outgrow the success rate and cost-effectiveness of rational drug development. For instance, the Center for Commercialization of Cancer Immunotherapy (C3i) in November 2017 started providing T cell receptor-beta sequencing facilities in its Biomarker and Diagnostic unit in Canada. Rising demand for personalized medicine is expected to help the immune repertoire sequencing market grow, as personalized medicine uses the human genetic profile to make decisions regarding disease diagnosis, prevention, and treatment.

Data Bridge Market Research analyses a growth in the global immune repertoire sequencing market in the forecast period 2022-2029. The expected CAGR of immune repertoire sequencing market tends to be around 6.95% in the mentioned forecast period. The market was valued at USD 149.54 million in 2021, and it would grow upto USD 255.98 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Global Immune Repertoire Sequencing Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Product Type (Assay Kits and Instruments), Application (Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases and Other), End-User (Diagnostics Labs, Biotechnology and Pharmaceuticals Companies, Academic and Research Institutes and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Market Players Covered

Illumina Inc. (U.S.), Thermo Fisher Scientific (U.S.), PacBio (U.S.), CD Genomics (U.S.), Agilent Technologies, Inc (U.S.).,F. Hoffmann-La Roche Ltd (Switzerland), BGI Group Guangdong (Japan), Takara Bio Inc. (Japan), Adaptive Biotechnologies (U.S.), Atreca, Inc. (U.S.)., iRepertoire, Inc. (U.S.)

Market Opportunities

  • Increased Partnerships Promote High Market Growth
  • Increasing Demand For Personalized Medicine

Market Definition

Human adaptive immune system protection is interfered with by receptors on the surface of T and B cells known as T-cell receptors and B-cell receptors. Next-generation sequencing has enabled the development of an emerging technology known as immune repertoire sequencing for probing complimentary, which works to determine the regions of these receptors. Single-cell approaches are most likely to dominate immune repertoire sequencing because they provide high-dimensional and in-depth information on smaller populations of interest, including antigen-binding cells. Thus, this is of great importance to the emerging market.

Global Immune Repertoire Sequencing Market Dynamics

Drivers

  • Increasing Research and Development

In the near future, increasing research and development and introducing novel products by key players are projected to be the primary drivers of global immune repertoire sequencing market growth. For instance, during the American Society of Hematology in 2016, ArcherDX, Inc. increased its product line by introducing Archer Immunoverse immune repertoire sequencing tests (ASH). Archer Immunoverse B Cell Receptor (BCR) tests were introduced in 2017 by ArcherDX, Inc. to define the human B cell repertoire.

  • Increased Government Support

Increase in support from the government for varied pharmacogenomics-based drug recovery is the major driver of the global immune repertoire sequencing market. In addition to this, the rapid rise in various therapeutic areas such as infectious diseases, cardiology, oncology, and pain management prompts the growth of the global immune repertoire sequencing market.

Opportunities

  • Increased Partnerships Promote High Market Growth

Another significant factor expected to contribute to the growth of the global immune repertoire sequencing market during the forecast period is manufacturer agreements and partnerships. For instance, ArcherDX and Ambry Genetics formed a collaboration in March 2018 to create new and breakthrough immunotherapies.

  • Increasing Demand For Personalized Medicine

The rise in demand for personalized medicine will positively influence the growth of the global immune repertoire sequencing market. In addition, nurturing the role of next-generation immune repertoire sequencing for personalized immune modulation will surely support the global immune repertoire sequencing market growth.

Restraints/Challenges

  • Lack of skilled professionals

The lack of qualified personnel to perform immune repertoire sequencing techniques developed in specialized laboratories could curb the growth of the immune repertoire sequencing market over a forecast period.

  • Accuracy Issues and Biased Techniques

Differentiating biological changes from errors and bias introduced in different phases is a challenge in immune repertoire sequencing. Due to insufficient scalability and sensitivity and limitations in supplying sufficient and reliable data, traditional and novel bioinformatics techniques such as high throughput screening, Haystack Heuristic, and others fall short. Furthermore, discrepancies in data collection and processing in different laboratories, as well as obstacles in immune repertoire sequencing systems, are some of the significant reasons that could limit the immune repertoire sequencing market's growth.

This immune repertoire sequencing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immune repertoire sequencing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Immune Repertoire Sequencing Market

The COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Our ongoing research is enhancing our research approach to guarantee that fundamental COVID-19 concerns and potential solutions are included.

Due to undermining clinical studies, insufficient supply chain management and raw material storage, and patient noncompliance, the COVID-19 pandemic has substantially impacted the worldwide immune repertoire sequencing market. Furthermore, the worldwide immune repertoire sequencing market has been significantly impacted by governments' reduced financing as a result of the pandemic. However, in the post-pandemic situation, the market is slowly improving as the funds are returning and it is expected to flourish at a much higher rate.  

Global Immune Repertoire Sequencing Market Scope

The immune repertoire sequencing market is segmented on the basis of product type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

Application

  • Cancer Immunotherapy
  • Biomarker Discovery
  • Autoimmune Diseases
  • Vaccine Development and Efficacy
  • Transplant Rejection and Tolerance
  • Infectious Diseases
  • Other

End-User

  • Diagnostics Labs
  • Biotechnology and Pharmaceuticals Companies
  • Academic and Research Institutes
  • Others

Immune Repertoire Sequencing Market Regional Analysis/Insights

The immune repertoire sequencing market is analysed and market size insights and trends are provided by country, product type, application and end-user as referenced above.

The major countries covered in the immune repertoire sequencing market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the immune repertoire sequencing market due to rapid increase in the demand for immunotherapy for cancer and other infectious diseases.

Asia-Pacific is expected to expand at a significant growth rate during the forecast period of 2022 to 2029 due to international collaborations for immune repertoire sequencing and developments.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Immune Repertoire Sequencing Market Share Analysis

The immune repertoire sequencing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immune repertoire sequencing market

Key players operating in the immune repertoire sequencing market include:

  • Illumina Inc. (U.S.)
  • Thermo Fisher Scientific (U.S.)
  • PacBio (U.S.)
  • CD Genomics (U.S.)
  • Agilent Technologies, Inc (U.S.).
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • BGI Group Guangdong (Japan)
  • Takara Bio, Inc. (Japan)
  • Adaptive Biotechnologies (U.S.)
  • Juno Therapeutics (U.S.)
  • Atreca, Inc. (U.S.)
  • irepertoire, Inc. (U.S.)


SKU-
Why Choose Us


Frequently Asked Questions

The global immune repertoire sequencing market is expected USD 255.98 million by 2029.
The global immune repertoire sequencing market is projected to grow at a CAGR of 6.95% during the forecast period of 2022-2029.
On the basis of application, the Immune Repertoire Sequencing Market is segmented into Cancer Immunotherapy, Biomarker Discovery, Autoimmune Diseases, Vaccine Development and Efficacy, Transplant Rejection and Tolerance, Infectious Diseases and Other.
The major players operating in the Immune Repertoire Sequencing Market are Illumina Inc. (U.S.), Thermo Fisher Scientific (U.S.), PacBio (U.S.), CD Genomics (U.S.), Agilent Technologies, Inc (U.S.).,F. Hoffmann-La Roche Ltd (Switzerland), BGI Group Guangdong (Japan), Takara Bio Inc. (Japan), Adaptive Biotechnologies (U.S.), Atreca, Inc. (U.S.)., iRepertoire, Inc. (U.S.).